纳米粒子在癌症治疗中的广泛利用激发了一个新的研究领域,称为癌症纳米医学。与传统的抗癌药物相比,纳米药物提供了一个有针对性的策略,消除副作用,并具有高疗效。凭借其广阔的表面积,可变孔径,高孔隙体积,丰富的表面化学和特异性结合亲和力,介孔二氧化硅纳米粒子(MPSNP)是癌症诊断和治疗的潜在候选者。然而,纳米粒子有几个瓶颈,包括对特定体液的特定毒性或亲和力,可以通过构建核壳纳米系统来满足需求。核壳化学,协同效应,核-壳纳米系统中的界面异质结增强了它们的稳定性,催化和物理化学属性,在癌症治疗中具有很高的性能。本文综述了致力于工程介孔核壳纳米系统的研究和开发,特别是二氧化硅纳米颗粒和Fe3O4@Au纳米颗粒,由于其独特的物理化学特性。此外,它强调了Fe3O4@Au和基于MPSNP的癌症治疗策略的最先进的磁性和光学属性。详细介绍了Fe3O4@Au和MPSN与药物结合的设计,受体,配体,并破坏肿瘤细胞和靶向药物递送。这篇综述作为一个基本的综合结构,指导未来研究基于Fe3O4@Au和MPSNP的核壳纳米系统用于癌症治疗的前景。
The extensive utilization of nanoparticles in cancer therapies has inspired a new field of study called cancer nanomedicine. In contrast to traditional anticancer medications, nanomedicines offer a targeted strategy that eliminates side effects and has high efficacy. With its vast surface area, variable pore size, high pore volume, abundant surface chemistry and specific binding affinity, mesoporous silica nanoparticles (MPSNPs) are a potential candidate for cancer diagnosis and treatment. However, there are several bottlenecks associated with nanoparticles, including specific toxicity or affinity towards particular body fluid, which can cater by architecting core-shell nanosystems. The core-shell chemistries, synergistic effects, and interfacial heterojunctions in core-shell nanosystems enhance their stability, catalytic and physicochemical attributes, which possess high performance in cancer therapeutics. This review article summarizes research and development dedicated to engineering mesoporous core-shell nanosystems, especially silica nanoparticles and Fe3O4@Au nanoparticles, owing to their unique physicochemical characteristics. Moreover, it highlights state-of-the-art magnetic and optical attributes of Fe3O4@Au and MPSNP-based cancer therapy strategies. It details the designing of Fe3O4@Au and MPSN to bind with drugs, receptors, ligands, and destroy tumour cells and targeted drug delivery. This review serves as a fundamental comprehensive structure to guide future research towards prospects of core-shell nanosystems based on Fe3O4@Au and MPSNP for cancer theranostics.